AI tool aims to predict liver cancer return after surgery

NCT ID NCT07062380

Recruiting now Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing an artificial intelligence (AI) model to see if it can predict whether early-stage liver cancer will come back within two years after surgery. About 353 adults with early-stage liver cancer will have standard surgery and then be monitored with scans. Their medical data and images will be used to train and check the AI's predictions. The goal is to improve follow-up care by identifying high-risk patients earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this AI tool could help doctors identify patients at high risk of cancer recurrence early, allowing for closer monitoring or timely treatment adjustments.
What could go wrong: This is an observational study, not a treatment trial. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATECELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATECELLULAR CARCINOMA HEPATECTOMY

Contacts and locations

Locations

Tongji Hospital
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.